About Plexision
Plexision is a Healthcare company based in Pittsburgh (United States) founded in 2008. It operates as a cellular biomarkers for transplantation and immunology diagnostics are developed. It operates on a HealthTech and Professional Services model. Plexision has raised $365 thousand across 2 funding rounds from investors including America’s Seed Fund and Richard King Mellon Foundation. Plexision offers products and services including Pleximmune TM, Pleximark TM, PlexCMV TM, and PlexCOVID-19 TM. Its focus areas include Biotechnology and Diagnostics. Its competitors include Abingdon Health, Genoptix, SkylineDX, Precipio Diagnostics and Biofluidica and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Cellular biomarkers are developed by Plexision for personalized diagnosis and drug development in solid organ transplantation, infectious diseases, and immunological disorders. Services are provided in areas such as transplant rejection, viral infections, COVID-19 testing, immune deficiency, and immuno-oncology. Custom RD projects are undertaken to integrate biomarker targets across all phases of drug development, from preclinical to post-marketing stages. The technology is adapted to assess disease risk, predict drug success for specific patients, and develop dosing recommendations for immunological drugs. Operations are based in a CLIA-certified laboratory located in Pittsburgh, PA, USA.
- Headquarters Pittsburgh, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website plexision.com
- Social LinkedIn X Facebook
- Total Equity Funding$365K (USD)
in 2 rounds
- Latest Funding Round$365K (USD), Seed
Jul 2025
- InvestorsAmerica’s Seed Fund
& 1 more
Products & Services of Plexision
Plexision offers a comprehensive portfolio of products and services, including Pleximmune TM, Pleximark TM, PlexCMV TM, and PlexCOVID-19 TM.
Predicts rejection risk after liver or intestine transplantation.
Assesses rejection likelihood after kidney transplantation in patients.
Measures cellular immunity levels to Cytomegalovirus in patients.
Measures cellular immunity levels to SARS-CoV-2 in individuals.
Funding Insights of Plexision
Plexision has successfully raised a total of $365K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $365 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $365,000
- Total Rounds 2
- Last Round Seed — $365,000
- First Round $218,396
(Sep 2020)
- Investors Count 2
All 2 funding rounds of Plexision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $365,000 | Seed | – | – | |
| Sep 2020 | $218,396 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Plexision
Plexision has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include America’s Seed Fund and Richard King Mellon Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Provides grants for conservation, economic development, and social impact programs. | 1947 | rkmf.org | Pittsburgh, United States |
Investor details for Plexision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Plexision
1 people are tracked at Plexision (1 in leadership).
| Name | Role | Group |
|---|---|---|
Rakesh Sindhi | Chief Scientific Officer | Leadership |
Complete people profiles for Plexision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Plexision
3 dated milestones of Plexision across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Plexision is founded.
- Funding First funding round of $218K.
- Funding Latest funding round, Seed, of $365K.
Competitors of Plexision
Plexision has 9 listed competitors in our database, 7 of them funded. They include Abingdon Health, Genoptix, SkylineDX, Precipio Diagnostics and Biofluidica, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abingdonhealth.com | 2008 | York, United Kingdom | $24.05M | 151 | Developer of immunoassays for diagnostic purposes | |
| genoptix.com | 1999 | Carlsbad, United States | $33.26M | 46 | Oncology diagnostics and informatics services | |
| skylinedx.com | 2005 | Rotterdam, Netherlands | – | – | Gene expression profiling tests are provided for personalized medicine. | |
| precipiodx.com | 1997 | New Haven, United States | – | – | Cancer diagnostics and second opinion tools are offered. | |
| biofluidica.com | 2007 | Chapel Hill, United States | $18.12M | 13 | Liquid biopsy tests utilizing CTCs are provided for cancer detection. | |
| elucidaoncology.com | 2014 | Santa Barbara, United States | $81.54M | – | Nanotechnology-based particle delivery platform is developed for oncology applications. | |
| jaxbio.com | 2020 | Netanya, Israel | $6M | – | Developer of an AI-based chip for genetic and epigenetic profiling | |
| repertoire.co.jp | 2014 | Ibaraki, Japan | $6.47M | – | TCR and BCR repertoire analysis services are offered. | |
| viviabiotech.com | 2007 | Tres Cantos, Spain | $7.52M | – | Precision medicine tests for hematologic cancers are developed. |
Detailed competitors of Plexision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Plexision
The website of Plexision (plexision.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▼ 22.8% vs previous month
Websites whose visitors overlap most with Plexision. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novasenta.com | 100% | 2.4K | #6,002,810 | View details | |
| ecmtherapeutics.com | 98% | 2.6K | #6,640,901 | View details | |
| bluespherebio.com | 97% | 2.5K | #6,529,430 | View details | |
pittbioforge.org | pittbioforge.org | 95% | – | #6,533,171 | – |
| peptilogics.com | 95% | 2.1K | #8,263,579 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Plexision
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Plexision (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Plexision
Complete news archive for Plexision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Plexision
Plexision was founded in 2008 and raised its 1st funding round 12 years after it was founded.
Plexision is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Plexision is a funded company, having raised a total of $365K across 2 funding rounds to date. The company's 1st funding round was a Grant of $218.4K, raised on Sep 2020.
Cellular biomarkers are developed by Plexision for personalized diagnosis and drug development in solid organ transplantation, infectious diseases, and immunological disorders. Services are provided in areas such as transplant rejection, viral infections, COVID-19 testing, immune deficiency, and immuno-oncology. Custom RD projects are undertaken to integrate biomarker targets across all phases of drug development, from preclinical to post-marketing stages. The technology is adapted to assess disease risk, predict drug success for specific patients, and develop dosing recommendations for immunological drugs. Operations are based in a CLIA-certified laboratory located in Pittsburgh, PA, USA.
Plexision's top competitors include Abingdon Health, Precipio Diagnostics and SkylineDX.
Plexision offers Pleximmune TM, Pleximark TM, PlexCMV TM, and PlexCOVID-19 TM.
Plexision has 2 investors. Key investors include America’s Seed Fund, and Richard King Mellon Foundation.